Key result
In-hospital exposure to NSAIDs in patients with systolic heart failure was associated with a longer length of stay (OR 4.67; 95% CI 4.10-5.25; p<0.001), but no significant difference in mortality.
Why the study?
Does in-hospital NSAID use increase length of stay or mortality in patients admitted with systolic heart failure?
Cohort (n=65,902)
Yes
Does in-hospital NSAID use increase length of stay or mortality in patients admitted with systolic heart failure?
Odds Ratio: 4.67 (95% CI 4.1–5.25)
p-value: p=<0.001
In-hospital NSAID use in patients with systolic heart failure is relatively low (4.1%) but is associated with a significantly longer length of stay.
BACKGROUND: Non-steroidal anti-inflammatory drugs are considered potentially harmful for patients with heart failure. OBJECTIVE: To determine the prevalence of in-hospital NSAID use, their type, associated diagnosis and impact in clinical outcomes among patients with a diagnosis of heart failure. METHODS: The University Health System Consortium Database was used to identify all first hospitalizations with an International Classification of Diseases-9 discharge diagnosis code of systolic heart failure as the primary diagnosis between January 1, 2011, and December 31st 2014. RESULTS: Among 65,902 patients admitted for a primary diagnosis of SHF, 2675 (4.1%) were exposed to NSAID. The most frequent NSAID used was ibuprofen (51.63%), followed by ketorolac (29.38%) naproxen (8.07%) celecoxib (5.61%), and others. On multivariable analyses, the length of stay of patients exposed to NSAID was longer compared to non-exposed (OR: 4.67, p < 0.001, 95% CI 4.10-5.25), but differences in mortality were not statistically different (OR: 0.90, p = 0.476, 95% CI 0.69-1.19). CONCLUSION: The use of NSAID in patients admitted with a primary diagnosis of systolic heart failure was low but was associated with longer length of stay. Further studies are needed to understand the impact of NSAID use in this patient population.
No takes yet. Share an insight, caveat, or question.
Álvarez et al. (2017) conducted a cohort in Systolic heart failure (n=65,902). Non-steroidal anti-inflammatory drugs (NSAIDs) vs. Non-exposed was evaluated on Longer length of stay (OR 4.67, 95% CI 4.10-5.25, p=<0.001). In-hospital exposure to NSAIDs in patients with systolic heart failure was associated with a longer length of stay (OR 4.67; 95% CI 4.10-5.25; p<0.001), but no significant difference in mortality.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: